CN102697753A - Roxithromycin compound and soft capsule preparation thereof - Google Patents
Roxithromycin compound and soft capsule preparation thereof Download PDFInfo
- Publication number
- CN102697753A CN102697753A CN2012101895804A CN201210189580A CN102697753A CN 102697753 A CN102697753 A CN 102697753A CN 2012101895804 A CN2012101895804 A CN 2012101895804A CN 201210189580 A CN201210189580 A CN 201210189580A CN 102697753 A CN102697753 A CN 102697753A
- Authority
- CN
- China
- Prior art keywords
- roxithromycin
- weight portions
- preparation
- soft capsule
- rubber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a roxithromycin compound preparation, in particular to a soft capsule preparation of a roxithromycin compound. A preparation method for soft roxithromycin capsules comprises the following steps of: adding 150 weight parts of roxithromycin and 100 to 150 weight parts of oily matrix into a solution preparation tank, mixing uniformly, and grinding with a colloid grinder; freezing the mixture of the roxithromycin and the oily matrix to the temperature of between 25 DEG C below zero and 40 DEG C below zero at the cooling rate of 2 to 15 DEG C per minute; vacuumizing, and heating to the temperature of between 15 and 25 DEG C in 2 to 6 hours; treating for 5 to 15 minutes in an ultrasonic emulsifier of which the frequency is 20 to 30KHz and the power is 20 to 500W; and preparing capsule wrappers of the soft roxithromycin capsules, injecting medicinal liquid, pelleting, sizing, wiping the capsules, and drying. The soft roxithromycin capsules are low in consumption of the oily matrix and high in stability.
Description
Technical field
The present invention relates to a kind of Roxithromycin compound formulation, specifically, relate to a kind of Roxithromycin chemical compound soft capsule prepn.
Background technology
Roxithromycin (Roxithromycin) has another name called 9-O-methoxy (ethoxy) methoxy 9-oxime erythromycin, and its molecular structure is that the fourteen-ring oral liquid of developing early 1980s is used macrolide antibiotics suc as formula shown in the I; These article were stable to gastric acid first in France's listing in 1988, and absorbance is high; Good effect, untoward reaction is little, and clinical effectiveness is remarkable; Moderate cost, most countries and area are widely used in clinical in the world at present.
In order to adapt to patient's needs, developed a lot of dosage forms about Roxithromycin, comprise capsule, soft capsule, various tablet, granule etc.Because the heavy bitter taste of Roxithromycin, so the tablet of Roxithromycin, granule are difficult for being accepted by the patient; And the capsule of Roxithromycin and soft capsule then more can adapt to the needs of extensive patients.
Patent application 200410041018.2 discloses a kind of Roxithromycin soft capsule and preparation method thereof, contains the Roxithromycin and the pharmaceutic adjuvant of effective dosage, and pharmaceutic adjuvant comprises diluent, antioxidant, solubilizing agent, cosolvent, pH regulator agent etc.By the normal capsules grain, contain Roxithromycin 0.01～0.25 gram in every medicinal liquid.Roxithromycin soft capsule preparation method: with the water-soluble adding glycerol of gelatin, transfer to suitable color, be incubated set aside for use after the vacuumize degassing; Solubilizing agent, antioxidant, pH regulator agent, dehydrated alcohol are added in the diluent, and Roxithromycin is dissolved in wherein, both mix homogeneously; 50-60 ℃ of reduction vaporization removed ethanol, gets settled solution; The medicinal liquid for preparing is poured in the pellet processing machine, finalized the design, put drying, scraping promptly gets.It is wide in variety to add adjuvant in the disclosed soft capsule of this patent, and stability is indeterminate.
Patent ZL200710108360.3 discloses a kind of soft capsule that contains Roxithromycin; It is 1%～85% Roxithromycin that wherein said content contains percentage by weight; 7%～95% oleaginous base and suspending agent; This soft capsule can show the beneficial effect that strengthens Roxithromycin, has more apparent stability of improving and treatment advantage than present commercially available prod.This soft capsule is to reach solubilization through adding suspending agent.
Summary of the invention
Goal of the invention of the present invention is to propose a kind of Roxithromycin preparation of soft capsule method.
In order to accomplish the object of the invention, the technical scheme of employing is:
The present invention relates to a kind of Roxithromycin preparation of soft capsule method, may further comprise the steps:
1. with Roxithromycin 150 weight portions, oleaginous base 100～150 weight portions; By weight joining in the Agitation Tank, mix homogeneously is crossed colloid mill;
2. the mixture with Roxithromycin and oleaginous base is refrigerated to-25～-40 ℃, and cooling rate is 2～15 ℃/min; Evacuation was warming up to 15～25 ℃ in 2～6 hours;
3. placing frequency then is that 20～30KHz, power are 20～500W ultrasonic emulsification instrument effect 5～15 minutes;
4. the rubber of preparation Roxithromycin soft capsule injects medicinal liquid, pelleting, typing, wiping ball, drying.
First optimal technical scheme of the present invention does, described oleaginous base is selected from least a in soybean oil, Semen Maydis oil, olive oil, the Oleum Arachidis hypogaeae semen and preferred soybean oil.
Second optimal technical scheme of the present invention does, in step (1), Roxithromycin is 150 weight portions, and oleaginous base is 120～150 weight portions, preferred 135～145 weight portions.
The 3rd optimal technical scheme of the present invention is in step (2), behind the evacuation, in 4～5 hours, to be warming up to 18～22 ℃.
The 4th optimal technical scheme of the present invention is in step (2), Roxithromycin and oleaginous base mixture to be refrigerated to-30～-40 ℃, preferred-30～-35 ℃; Cooling rate is 5～15 ℃/min, preferred 5～12 ℃/min.
The 5th optimal technical scheme of the present invention is that in step (3), the frequency of described ultrasonic emulsification instrument is that 20～28KHz, power are 30～300W; Optimized frequency is that 24～28KHz, power are 35～250W.
The 6th optimal technical scheme of the present invention is that in step (4), the prescription of said rubber is: gelatin 180～200 weight portions, glycerol 60～100 weight portions; Water 180～200 weight portions; Sorbitol 18～22 weight portions; Microcrystalline Cellulose 2～4 weight portions; Ethyl hydroxybenzoate 0.2～0.4 weight portion; Titanium dioxide 0.9～1.0 weight portion; Ethanol 120～150 weight portions.
The 7th optimal technical scheme of the present invention is that in step (4), the prescription of said rubber is: gelatin 200 weight portions; Glycerol 60～80 weight portions; Water 200 weight portions; Sorbitol 20 weight portions; Microcrystalline Cellulose 2～4 weight portions; Ethyl hydroxybenzoate 0.4 weight portion; Titanium dioxide 1.0 weight portions; Ethanol 150 weight portions.
The 8th optimal technical scheme of the present invention is that in step (4), the preparation technology of said rubber is:
(1) microcrystalline Cellulose adds suitable quantity of water and crosses colloid mill, and titanium dioxide adds suitable quantity of water and crosses colloid mill, and sorbitol is used an amount of hot water dissolving, and ethyl hydroxybenzoate is with 2 times of dissolve with ethanols, and is subsequent use;
(2) with in G & W, microcrystalline Cellulose serosity, titanium dioxide slurries, sorbitol solution, the ethyl hydroxybenzoate solution addingization glue jar, heating;
(3) treat to add gelatin after a jar interior temperature rises to 70 ℃, open stirring system and stir and make it melt and dissolved, temperature is controlled at below 80 ℃, treats that gelatin dissolves when even entirely, and open vacuum system evacuation is not till glue has bubble;
(4) glue of step (3) preparation is emitted, put the insulation of gelatin bucket and leave standstill use in 2～12 hours for 50 ℃～60 ℃.
The 9th optimal technical scheme of the present invention is that in step (4), the thickness of said rubber is 0.7～0.9mm, preferred 0.75～0.8mm.
Do further explanation and explanation in the face of content of the present invention down.
In the Roxithromycin preparation of soft capsule method of the present invention, at first adopt cryodesiccated technology, reduced the moisture in Roxithromycin and the oleaginous base.Because Roxithromycin is met water unstable, the present invention has removed the moisture content in Roxithromycin and the oleaginous base through freeze-dry process, thereby has guaranteed the stability of Roxithromycin.Secondly, the present invention has also adopted the technology of ultrasonic emulsification, and the mixture that will pass through after lyophilization is handled mixes.Not only reduced the consumption of oleaginous base in the drop pill; Can also medicine and oleaginous base mix more uniformly; Form the solid form of oil bag, thereby further avoid Roxithromycin to receive the influence of extraneous factor and react, guarantee the stability of Roxithromycin.
Roxithromycin preparation of soft capsule method of the present invention may further comprise the steps:
1. with Roxithromycin 150 weight portions, oleaginous base 100～150 weight portions, preferred 120～150 weight portions, further preferred 135～145 weight portions; By weight joining in the Agitation Tank, mix homogeneously is crossed colloid mill; Wherein, described oleaginous base is selected from least a in soybean oil, Semen Maydis oil, olive oil, the Oleum Arachidis hypogaeae semen, and preferred soybean oil; The consumption of oleaginous base reduces than the consumption of the actual use of prior art among the present invention, has reduced the patient burden, has avoided when taking medicine, eating into a large amount of adjuvants, has reduced greasy picked-up;
2. the Roxithromycin soybean oil blend is refrigerated to-25～-40 ℃, preferred-30～-40 ℃, more preferably-30～-35 ℃; Cooling rate is 2～15 ℃/min, preferred 5～15 ℃/min, preferred 5～12 ℃/min; Evacuation was warming up to 15～25 ℃ in 2～6 hours;
3. placing frequency then is that 20～30KHz, power are 20～500W ultrasonic emulsification instrument effect 5～15 minutes, obtains Roxithromycin and oleaginous base mixture; The frequency of described ultrasonic emulsification instrument is that 20～28KHz, power are 30～300W; Optimized frequency is that 24～28KHz, power are 35～250W; And in ultrasonic emulsification instrument, charge into nitrogen protection, and avoid oxidation Decomposition on the one hand, avoid Roxithromycin and oleaginous base to reuptake airborne moisture on the other hand, influence cryodesiccated effect; Wherein, the power of ultrasonic emulsification instrument confirms that according to the volume of mixture adopt the reaction vessel of 1 ~ 5L in the general operation process, its power is that 20～100W is advisable, and the routine that is chosen as those skilled in the art of this power is selected;
4. the rubber of preparation Roxithromycin soft capsule injects medicinal liquid, pelleting, typing, wiping ball, drying.
The prescription of said rubber is: gelatin 180～200 weight portions, glycerol 60～100 weight portions; Water 180～200 weight portions; Sorbitol 18～22 weight portions; Microcrystalline Cellulose 2～4 weight portions; Ethyl hydroxybenzoate 0.2～0.4 weight portion; Titanium dioxide 0.9～1.0 weight portion; Ethanol 120～150 weight portions.Be preferably: gelatin 200 weight portions; Glycerol 60～80 weight portions; Water 200 weight portions; Sorbitol 20 weight portions; Microcrystalline Cellulose 2～4 weight portions; Ethyl hydroxybenzoate 0.4 weight portion; Titanium dioxide 1.0 weight portions; Ethanol 150 weight portions.The thickness of rubber is 0.7～0.9mm, preferred 0.75～0.8mm.The inventor adopts the rubber character of prescription of the present invention and ratio more stable through screening test, but under the commercially available back condition normal temperature storage; And disintegration time is suitable, helps the absorption of medicine, increases bioavailability of medicament.
The specific embodiment of the present invention is done further explanation and explanation to invention, summary of the invention is not constituted restriction.
The specific embodiment
Embodiment 1～8: preparation Roxithromycin soft capsule
It is as shown in table 1 to fill a prescription:
Table 1:
Preparation technology is:
(1) with the Roxithromycin of formula ratio and oleaginous base by weight joining in the Agitation Tank, mix homogeneously is crossed colloid mill;
(2) mixture with Roxithromycin and oleaginous base is divided in the 100ml wide-mouth vial, is refrigerated to-40 ℃; Cooling rate is 2～15 ℃/min; Evacuation was warming up to 15～25 ℃ in 2～6 hours;
(3) placing volume then is that 1L, frequency are that 30KHz, power are 50W ultrasonic emulsification instrument effect 15 minutes, obtains Roxithromycin and oleaginous base mixture, and in ultrasonic emulsification instrument, charges into nitrogen protection;
(4) rubber of preparation Roxithromycin soft capsule injects medicinal liquid, pelleting, typing, wiping ball, drying.
The prescription of rubber is: gelatin 200 weight portions, glycerol 80 weight portions, water 200 weight portions, sorbitol 20 weight portions, microcrystalline Cellulose 2 weight portions, ethyl hydroxybenzoate 0.4 weight portion, titanium dioxide 1.0 weight portions, ethanol 150 weight portions.
The thickness of rubber is 0.75mm.
The preparation technology of rubber is:
(1) microcrystalline Cellulose adds suitable quantity of water and crosses colloid mill, and titanium dioxide adds suitable quantity of water and crosses colloid mill, and sorbitol is used an amount of hot water dissolving, and ethyl hydroxybenzoate is with 2 times of dissolve with ethanols, and is subsequent use;
(2) with in G & W, microcrystalline Cellulose serosity, titanium dioxide slurries, sorbitol solution, the ethyl hydroxybenzoate solution addingization glue jar, heating;
(3) treat to add gelatin after a jar interior temperature rises to 70 ℃, open stirring system and stir and make it melt and dissolved, temperature is controlled at below 80 ℃, treats that gelatin dissolves when even entirely, and open vacuum system evacuation is not till glue has bubble;
(4) glue of step (3) preparation is emitted, put the insulation of gelatin bucket and leave standstill use in 6 hours for 50 ℃～60 ℃.
Embodiment 9～13: preparation Roxithromycin soft capsule
It is as shown in table 2 to fill a prescription:
Table 2:
Preparation technology is:
(5) with the Roxithromycin of formula ratio and oleaginous base by weight joining in the Agitation Tank, mix homogeneously is crossed colloid mill;
(6) mixture with Roxithromycin and oleaginous base is divided in the 100ml wide-mouth vial, is refrigerated to-35 ℃; Cooling rate is 12 ℃/min; Evacuation was warming up to 20 ℃ in 5 hours;
(7) placing frequency then is that volume is that 1L, 28KHz, power are 35W ultrasonic emulsification instrument effect 10 minutes, obtains Roxithromycin and oleaginous base mixture; And in ultrasonic emulsification instrument, charging into nitrogen protection, the rubber of preparation Roxithromycin soft capsule injects medicinal liquid, pelleting, typing, wiping ball, drying.
The prescription of rubber is: gelatin 200 weight portions, glycerol 80 weight portions, water 200 weight portions, sorbitol 20 weight portions, microcrystalline Cellulose 2～4 weight portions, ethyl hydroxybenzoate 0.4 weight portion, titanium dioxide 1.0 weight portions, ethanol 150 weight portions.
The thickness of rubber is 0.8mm.
The preparation technology of rubber is with embodiment 1.
Embodiment 14～15: preparation Roxithromycin soft capsule
It is as shown in table 3 to fill a prescription:
Table 3:
Preparation technology is:
(8) with the Roxithromycin of formula ratio and oleaginous base by weight joining in the Agitation Tank, mix homogeneously is crossed colloid mill;
(9) mixture with Roxithromycin and oleaginous base is divided in the 100ml wide-mouth vial, is refrigerated to-30 ℃; Cooling rate is 5 ℃/min; Evacuation was warming up to 15 ℃ in 2 hours;
(10) placing volume then is that 5L, frequency are that 24KHz, power are 100W ultrasonic emulsification instrument effect 5～15 minutes, obtains Roxithromycin and oleaginous base mixture, and in ultrasonic emulsification instrument, charges into nitrogen protection;
5. the rubber of preparation Roxithromycin soft capsule injects medicinal liquid, pelleting, typing, wiping ball, drying.
The prescription of rubber, thickness and method for preparing are with embodiment 1.
Experimental example 1 Study on influencing factors
Roxithromycin soft capsule with the embodiment preparation; Simulation listing packing; Put in the clean seal container, (the condition held of 4500lx ± 500lx) 10 days was in the 5th day and the 10th day sampling and measuring at high temperature (40 ℃), high temperature (60 ℃), high humidity (relative humidity 90% ± 5%), high light respectively.Measure its outward appearance, content shape, disintegration time, related substance, content, experimental result is as shown in table 4:
Table 4: influence factor's experimental result
Can know through influence factor's experiment, the soft capsule of embodiment 1 preparation among the present invention, its disintegration time, dissolution, content and related substance have no significant change, and soft capsule of the present invention steady quality under high temperature, high humidity, high light is described.
Soft capsule to other embodiment preparations of the present invention carries out influence factor's experiment, obtains identical experimental result.
Embodiment 2 accelerated tests
Three batches 101201,101202,101203 simulation listing packings to the soft capsule of the embodiment of the invention 2 preparation; Put in the clean seal container; In temperature is that 40 ℃, relative humidity are 90% condition held 6 months; Respectively at 0,1,2,3, the sampling in June observes and measures, its accelerated test data are as shown in table 5.
Table 5: accelerated tests result
Can know through the accelerator experiment, the soft capsule of embodiment 2 preparations among the present invention, its disintegration, dissolution, content and related substance have no significant change, and explain that soft capsule quality of the present invention is stable.
Soft capsule to other embodiment preparations of the present invention carries out accelerated tests, obtains identical experimental result.
Embodiment 3: long-term experiment
Three batches 101101,101102,101103 simulation listing packings to the soft capsule of the embodiment of the invention 2 preparation; Put in the clean seal container; In temperature is that 25 ℃, relative humidity are 75% condition held 24 months; Observe mensuration respectively at sampling in 0,3,6,9,12,18,24 month, its long term test data are as shown in table 6.
Table 6: long-term experiment result
Can know through the accelerator experiment, the soft capsule of embodiment 3 preparations among the present invention, its disintegration time, dissolution, content and related substance have no significant change, and explain that soft capsule quality of the present invention is stable.
Soft capsule to other embodiment preparations of the present invention carries out long-term experiment, obtains identical experimental result.
Experimental example 4 contrast tests
Comparative Examples 1: adopt prescription and the method for preparing of embodiment 1, difference is not do in the method for preparing step lyophilizing and handles;
Comparative Examples 2: adopt prescription and the method for preparing of embodiment 1, difference is not do in the method for preparing step ultrasonic emulsification and handles;
Comparative Examples 3: the product that adopts patent 20071011083603 methods.
Other gets the product of embodiment 1, and simulation listing packing is carried out accelerated test according to the condition of Test Example 2.Experimental result is as shown in table 7:
Table 7:
Can know by contrast test; The technical scheme of the method for preparing that the present invention adopts obtains soft capsule and all is better than prior art in disintegration time, dissolution, aspect stable; And be better than Comparative Examples 1 and Comparative Examples 2; Explain that the present invention adopts the combination of ultrasonic emulsification and two technologies of lyophilizing, can prepare the Roxithromycin soft capsule that various aspects of performance all is improved.
Claims (10)
1. Roxithromycin preparation of soft capsule method is characterized in that described method for preparing may further comprise the steps:
(1) with Roxithromycin 150 weight portions, oleaginous base 100～150 weight portions; By weight joining in the Agitation Tank, mix homogeneously is crossed colloid mill;
(2) mixture with Roxithromycin and oleaginous base is refrigerated to-25～-40 ℃, and cooling rate is 2～15 ℃/min; Evacuation was warming up to 15～25 ℃ in 2～6 hours;
(3) placing frequency then is that 20～30KHz, power are 20～500W ultrasonic emulsification instrument effect 5～15 minutes;
(4) rubber of preparation Roxithromycin soft capsule injects medicinal liquid, pelleting, typing, wiping ball, drying.
2. Roxithromycin preparation of soft capsule method according to claim 1 is characterized in that, in step (1), described oleaginous base is selected from least a in soybean oil, Semen Maydis oil, olive oil, the Oleum Arachidis hypogaeae semen, and preferred soybean oil.
3. Roxithromycin preparation of soft capsule method according to claim 1 is characterized in that, in step (1), Roxithromycin is 150 weight portions, and oleaginous base is 120～150 weight portions, preferred 135～145 weight portions.
4. Roxithromycin preparation of soft capsule method according to claim 1 is characterized in that, in step (2), behind the evacuation, in 4～5 hours, is warming up to 18～22 ℃.
5. Roxithromycin preparation of soft capsule method according to claim 1 is characterized in that, in step (2), Roxithromycin and oleaginous base mixture is refrigerated to-30～-40 ℃, preferred-30～-35 ℃; Cooling rate is 5～15 ℃/min, preferred 5～12 ℃/min.
6. Roxithromycin preparation of soft capsule method according to claim 1 is characterized in that, in step (3), the frequency of described ultrasonic emulsification instrument is that 20～28KHz, power are 30～300W; Optimized frequency is that 24～28KHz, power are 35～250W.
7. Roxithromycin preparation of soft capsule method according to claim 1 is characterized in that, in step (4), the prescription of said rubber is: gelatin 180～200 weight portions, glycerol 60～100 weight portions; Water 180～200 weight portions; Sorbitol 18～22 weight portions; Microcrystalline Cellulose 2～4 weight portions; Ethyl hydroxybenzoate 0.2～0.4 weight portion; Titanium dioxide 0.9～1.0 weight portion; Ethanol 120～150 weight portions.
8. Roxithromycin preparation of soft capsule method according to claim 7 is characterized in that, in step (4), the prescription of said rubber is: gelatin 200 weight portions; Glycerol 60～80 weight portions; Water 200 weight portions; Sorbitol 20 weight portions; Microcrystalline Cellulose 2～4 weight portions; Ethyl hydroxybenzoate 0.4 weight portion; Titanium dioxide 1.0 weight portions; Ethanol 150 weight portions.
9. Roxithromycin preparation of soft capsule method according to claim 7 is characterized in that, in step (4), the preparation technology of said rubber is:
(1) microcrystalline Cellulose adds suitable quantity of water and crosses colloid mill, and titanium dioxide adds suitable quantity of water and crosses colloid mill, and sorbitol is used an amount of hot water dissolving, and ethyl hydroxybenzoate is with 2 times of dissolve with ethanols, and is subsequent use;
(2) with in G & W, microcrystalline Cellulose serosity, titanium dioxide slurries, sorbitol solution, the ethyl hydroxybenzoate solution addingization glue jar, heating;
(3) treat to add gelatin after a jar interior temperature rises to 70 ℃, open stirring system and stir and make it melt and dissolved, temperature is controlled at below 80 ℃, treats that gelatin dissolves when even entirely, and open vacuum system evacuation is not till glue has bubble;
(4) glue of step (3) preparation is emitted, put the insulation of gelatin bucket and leave standstill use in 2～12 hours for 50 ℃～60 ℃.
10. Roxithromycin preparation of soft capsule method according to claim 1 is characterized in that, in step (4), the thickness of said rubber is 0.7～0.9mm, preferred 0.75～0.8mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210189580 CN102697753B (en) | 2012-06-08 | 2012-06-08 | Roxithromycin soft capsule preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210189580 CN102697753B (en) | 2012-06-08 | 2012-06-08 | Roxithromycin soft capsule preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102697753A true CN102697753A (en) | 2012-10-03 |
| CN102697753B CN102697753B (en) | 2013-04-24 |
Family
ID=46891002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210189580 Active CN102697753B (en) | 2012-06-08 | 2012-06-08 | Roxithromycin soft capsule preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102697753B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951859A (en) * | 2017-12-25 | 2018-04-24 | 安徽永生堂药业有限责任公司 | A kind of roxithromycin soft capsule and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709273A (en) * | 2004-06-18 | 2005-12-21 | 秦引林 | Roxhthromycin soft capsule and its preparing method |
| CN101077351A (en) * | 2007-05-21 | 2007-11-28 | 姚俊华 | Soft capsules containing roxithromycin |
-
2012
- 2012-06-08 CN CN 201210189580 patent/CN102697753B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709273A (en) * | 2004-06-18 | 2005-12-21 | 秦引林 | Roxhthromycin soft capsule and its preparing method |
| CN101077351A (en) * | 2007-05-21 | 2007-11-28 | 姚俊华 | Soft capsules containing roxithromycin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951859A (en) * | 2017-12-25 | 2018-04-24 | 安徽永生堂药业有限责任公司 | A kind of roxithromycin soft capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102697753B (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940006270B1 (en) | Solvent system for an ionizable pharmacentical agent | |
| TW201114766A (en) | Pharmaceutical composition for a hepatitis C viral protease inhibitor | |
| CN104857517B (en) | A kind of miscellaneous Shandong amine soft capsule of grace and preparation method thereof | |
| NO333369B1 (en) | Process for Increasing the Concentration of a Pharmaceutically Active Ingredient to Fill Preparation Viscosity for Dosage Units and Soft Gelatin Capsule | |
| CN103159769B (en) | Doxofylline compound and medicine composition thereof | |
| CN102133225B (en) | Compound polyethylene glycol electrolyte pulvis and preparation method thereof | |
| CN101711746B (en) | Ganciclovir freeze-dry preparation for injection and preparation method thereof | |
| CN102697753B (en) | Roxithromycin soft capsule preparation thereof | |
| WO2014005363A1 (en) | 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol soft capsule and method for preparing same | |
| CN102784382A (en) | Argatroban drug composition and preparation method and application of argatroban drug composition | |
| CN102367229B (en) | Ethylenediamine diaceturate compound and pharmaceutical composition thereof | |
| CN102106846A (en) | Levogyration esmolol hydrochloride medicinal compositions and preparation method thereof | |
| CN103142509B (en) | A kind of injection bortezomib pharmaceutical composition | |
| CN104095816B (en) | Lutein ester nano-particle and preparation method thereof | |
| WO2012003804A1 (en) | Pharmaceutical composition of silybin and preparation method thereof | |
| CN102872002B (en) | Hydroxysafflor yellow A oil solution and preparation method and application thereof | |
| JP2021523195A (en) | HC-1119 formulation and its manufacturing method and use | |
| CN106692081B (en) | A kind of freeze-dried powder injection of pantoprazole sodium and preparation method | |
| CN103520186B (en) | Pharmaceutical composition of a kind of fat-soluble vitamin for injection and preparation method thereof | |
| CN102507767B (en) | A kind of injection Alprostadil detection method | |
| CN103304600B (en) | A kind of voriconazole phosphate ester trihydrate and its preparation method and application | |
| CN103040737B (en) | Drug composition containing lansoprazole compound and preparation method of drug composition | |
| CN107865870A (en) | Preparation and application as EV71 viruses and the phosphatide complexes of CAV16 viral inhibitors | |
| CN106214679A (en) | Phenol fiber crops U.S. soft gelatin pharmaceutical and preparation method thereof | |
| WO2024188095A1 (en) | Preparation method for large-size boronophenylalanine lyophilized powder for injection and lyophilized powder for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: ZHEJIANG WEIKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: ZHEJIANG WECOME MEDICINE LNDUSTRY CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 323000 No. 2 Pine Road, Lishui Economic Development Zone, Zhejiang, China Patentee after: ZHEJIANG WEIKANG PHARMACEUTICAL CO., LTD. Address before: 323000 Zhejiang Province, Lishui City Economic Development Zone Shuige Industrial Zone Patentee before: Zhejiang Wecome Medicine lndustry Co., Ltd. |